Navigation Links
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Date:5/14/2008

,8) The rigorous study design included a 12 to 36 week stabilization phase which was followed by a longer-term, randomized, double-blind treatment phase that had a mean duration of exposure of 213.2 days for SEROQUEL and 152.4 days for placebo. (9)

In both studies, patients with bipolar I disorder whose most recent episode was manic, depressed, or mixed, were treated with either SEROQUEL (flexible dosing between 400 and 800 mg per day in divided doses) plus lithium-or-divalproex or placebo plus lithium-or-divalproex. (9) The primary endpoint, which was time to recurrence of a depressive, manic, or mixed mood event, was significant for SEROQUEL compared with placebo in both studies. (9) Pooled study results indicated that patients treated with SEROQUEL plus lithium-or-divalproex (n=646) had a risk reduction of 70% relative to those treated with placebo plus lithium-or-divalproex (n=680) for time to recurrence of a mood event (HR: 0.30; 95% CI: 0.24, 0.37; p<0.001). (9) This reduction in risk was significant for both recurrence of manic episodes (HR: 0.30; 95% CI: 0.22, 0.41; p less than 0.001) and recurrence of depressive episodes (HR: 0.30; 95% CI: 0.23, 0.40; p less than 0.001). The proportion of patients who relapsed when treated with SEROQUEL was 19.3% [125/646] versus 50.4% [343/680] of patients on placebo. (9)

Adverse events in these trials, which were monitored during both the open-label stabilization phase and the randomized controlled-phase, were generally consistent with those reported in short term, placebo-controlled trials for SEROQUEL. In the pooled data of the two clinical studies, a greater incidence of blood glucose increases to hyperglycemic levels (Greater Than or Equal to 126mg/dL) was observed in patients randomized to SEROQUEL plus lithium-or-divalproex than in patients randomized to placebo plus lithium-or-divalproex. The SEROQUEL prescribing information was updated in July 2007 to reflect the increases in blood glucose levels obs
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
2. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
3. FDA Approves Health Claim for Brown Rice
4. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
5. FDA approves HeartMate II mechanical heart pump for heart-failure patients
6. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
7. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
8. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
9. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
10. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
11. VeriPrime Approves New Best Practices for Beef Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Fairfax, Va., April 23, 2014 The American Society ... guideline, "The Role of Postoperative Radiation Therapy for ... the use of adjuvant radiation therapy in the ... is published in the May-June 2014 issue of ... clinical practice journal of ASTRO. The full-length guideline ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... Occupational and Leisure Time Physical Activity on Mobility Limitation ... midlife increases the risk of mobility limitation in old ... is found in a study which followed up 5,200 ... conducted at the Gerontology Research Center in Finland and ... labor is often repetitive, wears the body and lasts ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... technique could pave the way toward screening people at ... may foreshadow malignancies, researchers from the University of Colorado ... in cancer is prevention, said researcher Wilbur A. Franklin, ... Health Sciences Center. Our goal would be to develop ...
... Dr. Peter Farrell to remain Chairman of the Board, ... RMD ),announced today that its board of directors ... the company. Effective January,1, 2008, Kieran T. Gallahue will ... board of directors. Mr. Gallahue, 44, will succeed Dr. ...
... United States,Government, through the U.S. Agency for International ... in equipment and technical,assistance to the Government of ... This announcement follows the provision of an initial ... Hellenic Red Cross for emergency,fire fighting equipment and ...
... members of SEIU UHW-West and 121RN, their, first ... hospital, BURBANK, Calif., Aug. 30 Caregivers at ... United Healthcare Workers -,West (UHW) and SEIU 121RN, reached ... Medical Center. The contract, which expires,Sept. 30, 2011, grants ...
... (ret), former White House National Drug Policy,Director (1996- 2001), ... widely cited terrorism and drug policy expert in the ... State Capitol rally for,recovery and treatment at 11 AM ... speaking will be California HHS Secretary Kimberly Belshe and,State ...
... Company Refuses to Pay Hospital ... Market-Competitive Rates, SAN DIEGO, ... against Blue Shield, the large insurance company,that is attempting to force ... "Blue Shield,s calculated and aggressive negotiating tactics are,designed to break ...
Cached Medicine News:Health News:New technique detects specific chromosomal damage, may indicate lung cancer risk 2Health News:ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008. 2Health News:Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract 2Health News:4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote 'Recovery Happens!' Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento 2Health News:Alvarado Hospital Files Countersuit Against Blue Shield 2Health News:Alvarado Hospital Files Countersuit Against Blue Shield 3
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
Ultrasonic Pachymeter UP-1000 is fast, accurate corneal thickness measurements....
... pachymeter, with large high resolution LCD touch ... 300P is a portable, digital pachymeter which ... of a high frequency, low noise probe ... immediately upon application of the probe along ...
... pachymeter, with compact LCD screen and optional ... portable, weighing slightly more than 2 lbs ... large liquid crystal display. The combination of ... fast precise algorithm enables measurement immediately upon ...
... mounted on a stick to make ... are 37 mm square. They are ... 50PD. Plus red square. Now shipping ... prism on stainless steel stick. Specify ...
Medicine Products: